Table 2 Primary and secondary outcomes in three groups.
Group, No. (%) | mITT | PPS | ||||
|---|---|---|---|---|---|---|
120 mg/day CEP | 60 mg/day CEP | Placebo | 120 mg/day CEP | 60 mg/day CEP | Placebo | |
No. | 65 | 68 | 55 | 57 | 52 | 43 |
Primary outcome, time to negative | ||||||
Outcome event (%) | 65 (100) | 68 (100) | 55 (100) | 57 (100) | 52 (100) | 43 (100) |
RMST (95%CI), days* | 5.71 (5.00,6.42) | 5.01 (4.37, 5.66) | 5.78 (4.88, 6.68) | 5.63 (4.86, 6.41) | 4.85 (4.12, 5.58) | 5.72 (4.69, 6.75) |
Difference of RMST (95%CI) | -0.07 (-1.12, 1.07) | -0.77(-1.88, 0.34) | - | -0.09(-1.38, 1.20) | -0.87(-2.14, 0.39) | - |
Hazard Ratio (95%CI)† | 1.10 (0.76, 1.60) | 1.40 (0.97, 2.01) | - | 1.11 (0.73, 1.68) | 1.56 (1.03,2.37) | - |
P value†† | 0.606 | 0.072 | - | 0.619 | 0.035 | - |
Secondary outcomes | ||||||
Patients developed to pneumonia or severe COVID-19 — no.(%) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
SARS-CoV-2 returned to positive after turning negative — no.(%) | 2 (3.1) | 1 (1.5) | 3 (5.5) | 2 (3.5) | 1 (1.9) | 3 (7.0) |
Hospitalization for COVID-19 — no.(%) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
